Second, Pfizer's forward dividend yield stands at 7.47%. At first glance, the drugmaker's dividend payout ratio of 122.5% ...

Tvardi Therapeutics Inc. research and ratings by Barron's. View TVRD revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Real-time index price for KBW Finsec Dividend Yield Index (KDX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...

In light of this, income investors may be better off looking at ASX dividend shares instead of term deposits. The first ASX dividend share that could be a buy according to analysts is global ...

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.